{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000081","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.640953+00:00","generated_at":"2026-06-13T01:29:06.301106+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Pfizer restructures R&D, elevates Oncology as standalone unit; CDO William Pao departing Aug 15","bullets":["Pfizer restructures R&D, making Oncology a standalone unit; Dr. Chris Boshoff becomes Chief Oncology R&D Officer, EVP.","Dr. William Pao, Chief Development Officer, EVP, role eliminated; he will depart effective August 15, 2023.","Severance includes one year base salary and target bonus, two years welfare benefits, vesting of sign-on awards.","Reorganization driven by planned investment in Oncology, including proposed acquisition of Seagen Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000081","json":"https://secwatch.observer/filing/0000078003-23-000081.json","markdown":"https://secwatch.observer/filing/0000078003-23-000081.md","text":"https://secwatch.observer/filing/0000078003-23-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/pfe-20230721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T01:29:06.301106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bee25f4ac","claim":"William Pao departed as Chief Development Officer, Executive Vice President at PFIZER INC.","evidence_excerpt":"As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Development Officer, Executive Vice President"}],"fact_type":"executive_change"},{"claim_id":"4cd06edf10","claim":"Chris Boshoff was appointed as Chief Oncology Research and Development Officer, Executive Vice President at PFIZER INC.","evidence_excerpt":"Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Oncology Research and Development Officer, Executive Vice President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}